Mersana Therapeutics (MRSN) Q4 2024 earnings summary

Executive summary

• Reported positive initial clinical data and additional Fast Track designation for lead Dolasynthen ADC, Emi-Le, with expansion of phase I trial in TNBC patients previously treated with topo-1 ADCs.

• Advanced phase I dose escalation for XMT-2056, a STING agonist ADC targeting HER2, with initial pharmacodynamic data expected in 2025.

• Collaborations with Johnson & Johnson, Merck KGaA, and GSK continue to progress.

Financial highlights

• Ended 2024 with $134.6 million in cash, cash equivalents, and marketable securities, supporting operations into 2026.

• Q4 2024 collaboration revenue was $16.4 million, up from $10.7 million in Q4 2023; full year 2024 collaboration revenue was $40.5 million, up from $36.9 million in 2023.

• Net loss for Q4 2024 was $14.1 million ($0.11 per share), improved from $19.5 million ($0.16 per share) in Q4 2023; full year 2024 net loss was $69.2 million ($0.56 per share), down from $171.7 million ($1.48 per share) in 2023.

• R&D expenses for 2024 were $73.0 million, down from $148.3 million in 2023; G&A expenses were $40.8 million, down from $59.5 million.

• Net cash used in operating activities for Q4 2024 was $19.3 million; full year 2024 was $82.3 million.

Outlook and guidance

• Capital resources expected to support current operating plan into 2026, excluding potential future milestone or collaboration payments.

• Additional data from dose escalation and backfill for Emi-Le expected later in 2024; initial pharmacodynamic data for XMT-2056 anticipated in 2025.